Drug Information

General Information
Drug ID
DR00299
Drug Name
Indinavir
Synonyms
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide; Crixivan; Crixivan (TM); Crixivan (TN); IDV; Indinavir (*1:1 Sulfate salt*); Indinavir [USAN]; Indinavir, Sulfate (1:1); L 735524; L-735 524; L-735,524; L-735524; MK-639; N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; Propolis+Indinavir; RS-253
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD11: 1C62.Z] Approved [1]
Therapeutic Class
Anti-HIV Agents
Structure
3D MOL 2D MOL
Formula
C36H47N5O4
Canonical SMILES
CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5
InChI
InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1
InChIKey
CBVCZFGXHXORBI-PXQQMZJSSA-N
CAS Number
CAS 150378-17-9
Pharmaceutical Properties Molecular Weight 613.8 Topological Polar Surface Area 118
Heavy Atom Count 45 Rotatable Bond Count 12
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 7
XLogP
2.8
PubChem CID
5362440
PubChem SID
10317595 , 10317604 , 10317607 , 103179607 , 104322011 , 104829412 , 124892212 , 126628679 , 127336447 , 127336448 , 127336449 , 127336450 , 127602164 , 14765204 , 14862973 , 17422095 , 26697187 , 29211926 , 46391630 , 46392153 , 46392154 , 46392339 , 46393133 , 46393134 , 46393135 , 46393136 , 46393839 , 46393841 , 46393842 , 46393914 , 46506442 , 50064484 , 583813 , 601472 , 7846196 , 7888933 , 7979603 , 8030462 , 8187130 , 822078 , 824057 , 830610 , 832455 , 832456 , 832457 , 834483 , 9263 , 92717923 , 93166536 , 93167159
ChEBI ID
ChEBI:44032
TTD Drug ID
D0V7CF
DT(s) Transporting This Drug MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data P-GP Transporter Info Km = 0.47 microM High five cells-MDR1 [4]
References
1 Indinavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
3 Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
4 HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998 Mar 17;37(11):3594-601.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.